Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)

Phase 2CompletedNCT01946971

Seoul National University Hospital12 enrolled

Overview

This study is crossover study to evaluate safety and efficacy of lansoprazole in preterm infants with gastroesophageal reflux.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Premature Infants Gastroesophageal Reflux

Interventions

LansoprazoleDRUG

PlaceboDRUG

Eligibility

Sex: ALLMax age: 6 Months

Medical Language ↔ Plain English

Inclusion Criteria: * preterm infant * symptoms suspecting gastroesophageal reflux Exclusion Criteria: * unstable general conditions due infection or acute illness * congenital anomaly in upper gastrointestinal tract including esophagus * drug history of H2, proton pump inhibitor, blocker during last 1 week * medication of warfarin, carbamazepine, phenytoin, rifampin * inappropriate clinical conditions judged by researchers

Locations (1)

Seoul National University Hospital

Seoul, South Korea